吉非替尼治疗晚期复治的非小细胞肺癌的临床观察(2)
[2]Herbst RS, MaddoxAM,Rothenberg ML,et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solidtumors: results of a phaseⅠtrial[J].J Clin Oncol, 2002,20(18)∶3815-3825.
[3]CiardielloF,CaputoR,Bianco R,et al.Antitumor effect and potentiationof cytotoxic drugs activityin human cancer cells by ZD-1839 (Iressa).an epidermal growth factor receptor selective tyrosine kinase inhibitor[J].Clin Cancer Res,2000,6(5):2053 .
[4]Mendelson J.Blockade of receptors for growth factors: an anticancer therapythe fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture[J].Clin Cancer Res,2000,6(3)∶747-753.
[5]Ryan PD,Chabner BA.On receptor inhibitors and chemotherapy[J].Clin Cancer Res,2000,6(12)∶4607-4609.
[6]Nakagawa K,Tamura T,Negoro S,et al.PhaseⅠpharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib('Iressa',ZD1839)in Japanese patients with solid m alignant tumors[J]. Ann Oncol,2003,14(6):922.
[7] Fukuoka M, Yano S, Giaccone G,et al.Multi-institutional randomized phase Ⅱtrial of gefitinib for previously treated patients with advancednon-small-cell lung cancer(The IDEALⅠTrial)[corrected][J].J Clin Oncol,2003,21(12):2237.
[8]Argiris A, Mittal N.Gefitinib as first-line, compassionate use therapy in patients with advanced non- small-cell lung cancer[J].Lung Cancer,2004,43(3):317-322.
(收稿日期：2007-03-20)
[ 上 页 ], 百拇医药(徐艳霞 徐 媺 高 炜)
[3]CiardielloF,CaputoR,Bianco R,et al.Antitumor effect and potentiationof cytotoxic drugs activityin human cancer cells by ZD-1839 (Iressa).an epidermal growth factor receptor selective tyrosine kinase inhibitor[J].Clin Cancer Res,2000,6(5):2053 .
[4]Mendelson J.Blockade of receptors for growth factors: an anticancer therapythe fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture[J].Clin Cancer Res,2000,6(3)∶747-753.
[5]Ryan PD,Chabner BA.On receptor inhibitors and chemotherapy[J].Clin Cancer Res,2000,6(12)∶4607-4609.
[6]Nakagawa K,Tamura T,Negoro S,et al.PhaseⅠpharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib('Iressa',ZD1839)in Japanese patients with solid m alignant tumors[J]. Ann Oncol,2003,14(6):922.
[7] Fukuoka M, Yano S, Giaccone G,et al.Multi-institutional randomized phase Ⅱtrial of gefitinib for previously treated patients with advancednon-small-cell lung cancer(The IDEALⅠTrial)[corrected][J].J Clin Oncol,2003,21(12):2237.
[8]Argiris A, Mittal N.Gefitinib as first-line, compassionate use therapy in patients with advanced non- small-cell lung cancer[J].Lung Cancer,2004,43(3):317-322.
(收稿日期：2007-03-20)
[ 上 页 ], 百拇医药(徐艳霞 徐 媺 高 炜)